Recent News

• 05.21.2025 - Senior Director, Statistical Programming
• 05.20.2025 - Phase 2 TRANQUILITY Trial Topline Data
• 05.20.2025 - Phase 2 TRANQUILITY Trial Topline Data
• 05.20.2025 - Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
• 05.20.2025 - Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
• 05.19.2025 - Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
• 05.19.2025 - Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
• 05.02.2025 - Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
• 05.02.2025 - Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
• 04.23.2025 - Daniil Gataulin

Recent Filings

• 05.20.2025 - 8-K Current report
• 05.20.2025 - EX-99.1 EX-99.1
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.02.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.02.2025 - EX-99.1 EX-99.1
• 05.02.2025 - 8-K Current report
• 04.21.2025 - ARS Annual Report to Security Holders
• 04.21.2025 - DEF 14A Other definitive proxy statements